

FORM PTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				RTSP-0240	
				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR <b>10/019470</b> )	
INTERNATIONAL APPLICATION NO. <b>PCT/US00/19019</b>		INTERNATIONAL FILING DATE <b>12 July 2000</b>		PRIORITY DATE CLAIMED <b>19 July 1999</b>	
TITLE OF INVENTION <b>Antisense Modulation of Liver Glycogen Phosphorylase Expression</b>					
APPLICANT(S) FOR DO/EO/US <b>MONIA, Brett P. and COWSERT, Lex M.</b>					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under <u>35 U.S.C. 371</u>.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.</li> <li>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> <li>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</li> <li>12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</li> </ol> <p><b>Items 13 to 20 below concern document(s) or information included:</b></p> <ol style="list-style-type: none"> <li>13. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>15. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>16. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>17. <input type="checkbox"/> A substitute specification.</li> <li>18. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li>20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li>22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail</li> <li>23. <input checked="" type="checkbox"/> Other items or information:  <p>1) Courtesy copy of the International Application; 2) Statement to support filing and submission in accordance with 37 CFR 1.821-1.825; 3) Paper and disk copy of Amended Sequence Listing; 4) Return post card.</p> </li> </ol>					

531 Rec'd PCT

28 DEC 2001

U.S. APPLICATION NO. (IF KNOWN) SEE 37 CFR <b>10/019470</b>	INTERNATIONAL APPLICATION NO. <b>PCT/US00/19019</b>	ATTORNEY'S DOCKET NUMBER <b>RTSP-0240</b>
--	--	--

24. The following fees are submitted:.

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... **\$1040.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... **\$890.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... **\$740.00**
- ☒ International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... **\$710.00**
- ☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... **\$100.00**

**ENTER APPROPRIATE BASIC FEE AMOUNT =****CALCULATIONS PTO USE ONLY**

Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	18 - 20 =	0	x \$18.00	<b>\$0.00</b>	
Independent claims	1 - 3 =	0	x \$84.00	<b>\$0.00</b>	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>	

**TOTAL OF ABOVE CALCULATIONS = \$710.00**

☒ Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.

**\$355.00****SUBTOTAL = \$355.00**

Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).

**\$0.00****TOTAL NATIONAL FEE = \$355.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

**\$0.00****TOTAL FEES ENCLOSED = \$355.00**

Amount to be:	\$
refunded	
charged	\$

- a. ☒ A check in the amount of **\$355.00** to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **50-1619**. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata, Registration No. 32,257  
Kathleen A. Tyrrell, Registration No. 38,350  
Licata & Tyrrell P.C.  
66 East Main Street  
Marlton, New Jersey 08053

Tel: 856-810-1515  
Fax: 856-810-1454

SIGNATURE

Jane Massey Licata

NAME

32,257

REGISTRATION NUMBER

December 28, 2001

DATE

10/019470  
531 Rec'd PCT 28 DEC 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RTSP-0240  
Inventors: Monia and Cowsert  
Serial No.: Not yet assigned  
Filing Date: Herewith  
Examiner: Not yet assigned  
Group Art Unit: Not yet assigned  
Title: ANTISENSE MODULATION OF LIVER GLYCOGEN  
PHOSPHORYLASE EXPRESSION

"Express Mail" Label No. EV017478055US  
Date of Deposit December 28, 2001

I hereby certify that this paper is being deposited  
with the United States Postal Service "Express Mail  
Post Office to Addressee" service under 37 CFR 1.10  
on the date indicated above and is addressed to the  
Assistant Commissioner for Patents, Washington,  
D.C. 20231.

By Jane Massey Licata  
Typed Name: Jane Massey Licata, Reg. No. 32,257

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

PRELIMINARY AMENDMENT

It is respectfully requested that the Sequence Listing of the  
instant specification be deleted and replaced with the amended  
Sequence Listing provided herewith. A paper copy and a CRF copy of  
the amended Sequence Listing are provided herewith.

The replacement Sequence Listing has been amended to conform  
with the current Sequence Listing Rules.

Attorney Docket No.: RTSP-0240  
Inventors: Monia and Cowsert  
Serial No.: Not yet assigned  
Filing Date: Herewith  
Page 2

No new matter has been added by this amendment.

Respectfully submitted,

*Jane Massey Licata*

Jane Massey Licata  
Registration No. 32,257

Date: December 28, 2001

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515

10/019470

531 Rec'd PCT 28 DEC 2001

1

## SEQUENCE LISTING

<110> Brett P. Monia  
Lex M. Cowser

<120> ANTISENSE MODULATION OF LIVER GLYCOGEN PHOSPHORYLASE EXPRESSION

<130> RTSP-0240

<150> US 09/357,071

<151> 1999-07-19

<160> 47

<210> 1

<211> 2828

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (114)..(2657)

<400> 1

gttgaaagct cctggcgcg cggggcggac tccacccctg cccggcagcc cagcgcctcc 60

ggccgcactt ccagctctct gcgcagcccg ccgcgcagcc cgccgccccca gcc atg 116  
Met  
1

ggc gaa ccg ctg aca gac cag gag aag cgg cgg cag atc agc atc cgc 164  
Gly Glu Pro Leu Thr Asp Gln Glu Lys Arg Arg Gln Ile Ser Ile Arg  
5 10 15

ggc atc gtg ggc gtg gag aac gtg gca gag ctg aag aag agt ttc aac 212  
Gly Ile Val Gly Val Glu Asn Val Ala Glu Leu Lys Lys Ser Phe Asn  
20 25 30

cgg cac ctg cac ttc acg ctg gtc aag gac cgc aac gtg gcc acc acc 260  
Arg His Leu His Phe Thr Leu Val Lys Asp Arg Asn Val Ala Thr Thr  
35 40 45

cgc gac tac tac ttc gcg ctg gcg cac acg gtg cgg gac cac ctg gtg 308  
Arg Asp Tyr Tyr Phe Ala Leu Ala His Thr Val Arg Asp His Leu Val  
50 55 60 65

ggg cgc tgg atc cgc acg cag cag cac tac tac gac aag tgc ccc aag 356  
Gly Arg Trp Ile Arg Thr Gln Gln His Tyr Tyr Asp Lys Cys Pro Lys  
70 75 80

agg gaa tat tac ctc tct ctg gaa ttt tac atg ggc cga aca tta cag 404  
Arg Glu Tyr Tyr Leu Ser Leu Glu Phe Tyr Met Gly Arg Thr Leu Gln  
85 90 95

aac acc atg atc aac ctc ggt ctg caa aat gcc tgt gat gag gcc att 452  
Asn Thr Met Ile Asn Leu Gly Leu Gln Asn Ala Cys Asp Glu Ala Ile  
100 105 110

tac cag ctt gga ttg gat ata gaa gag tta gaa gaa att gaa gaa gat 500

10/019470

Tyr	Gln	Leu	Gly	Leu	Asp	Ile	Glu	Glu	Leu	Glu	Glu	Ile	Glu	Glu	Asp		
115						120					125						
gct	gga	ctt	ggc	aat	ggt	ggt	ctt	ggg	aga	ctt	gct	gcc	tgc	ttc	ttg	548	
Ala	Gly	Leu	Gly	Asn	Gly	Gly	Leu	Gly	Arg	Leu	Ala	Ala	Cys	Phe	Leu		
130					135					140					145		
gat	tcc	atg	gca	acc	ctg	gga	ctt	gca	gcc	tat	gga	tac	ggc	att	cgg	596	
Asp	Ser	Met	Ala	Thr	Leu	Gly	Leu	Ala	Ala	Tyr	Gly	Tyr	Gly	Ile	Arg		
				150					155						160		
tat	gaa	tat	ggg	att	ttc	aat	cag	aag	atc	cga	gat	gga	tgg	cag	gta	644	
Tyr	Glu	Tyr	Gly	Ile	Phe	Asn	Gln	Lys	Ile	Arg	Asp	Gly	Trp	Gln	Val		
			165					170						175			
gaa	gaa	gca	gat	gat	tgg	ctc	aga	tat	gga	aac	cct	tgg	gag	aag	tcc	692	
Glu	Glu	Ala	Asp	Asp	Trp	Leu	Arg	Tyr	Gly	Asn	Pro	Trp	Glu	Lys	Ser		
			180					185					190				
cgc	cca	gaa	ttc	atg	ctg	cct	gtg	cac	ttc	tat	gga	aaa	gta	gaa	cac	740	
Arg	Pro	Glu	Phe	Met	Leu	Pro	Val	His	Phe	Tyr	Gly	Lys	Val	Glu	His		
			195				200					205					
acc	aac	acc	ggg	acc	aag	tgg	att	gac	act	caa	gtg	gtc	ctg	gct	ctg	788	
Thr	Asn	Thr	Gly	Thr	Lys	Trp	Ile	Asp	Thr	Gln	Val	Val	Leu	Ala	Leu		
210					215					220					225		
cca	tat	gac	acc	ccc	gag	ccc	ggc	tac	atg	aat	aac	act	gtc	aac	acc	836	
Pro	Tyr	Asp	Thr	Pro	Glu	Pro	Gly	Tyr	Met	Asn	Asn	Thr	Val	Asn	Thr		
				230					235						240		
atg	cgc	ctc	tgg	tct	gct	cgg	gca	cca	aat	gac	ttt	aac	ctc	aga	gac	884	
Met	Arg	Leu	Trp	Ser	Ala	Arg	Ala	Pro	Asn	Asp	Phe	Asn	Leu	Arg	Asp		
				245				250						255			
ttt	aat	gtt	gga	gac	tac	att	cag	gct	gtg	ctg	gac	cga	aac	ctg	gcc	932	
Phe	Asn	Val	Gly	Asp	Tyr	Ile	Gln	Ala	Val	Leu	Asp	Arg	Asn	Leu	Ala		
			260					265					270				
gag	aac	atc	tcc	cgg	gtc	ctc	tat	ccc	aat	gac	aat	ttt	ttt	gaa	ggg	980	
Glu	Asn	Ile	Ser	Arg	Val	Leu	Tyr	Pro	Asn	Asp	Asn	Phe	Phe	Glu	Gly		
			275				280					285					
aag	gag	cta	aga	ttg	aag	cag	gaa	tac	ttt	gtg	gtg	gct	gca	acc	ttg	1028	
Lys	Glu	Leu	Arg	Leu	Lys	Gln	Glu	Tyr	Phe	Val	Val	Ala	Ala	Thr	Leu		
290					295					300					305		
caa	gat	atc	atc	cgc	cgt	ttc	aaa	gcc	tcc	aag	ttt	ggc	tcc	acc	cgt	1076	
Gln	Asp	Ile	Ile	Arg	Arg	Phe	Lys	Ala	Ser	Lys	Phe	Gly	Ser	Thr	Arg		
				310					315						320		
ggt	caa	gga	act	gtg	ttt	gat	gcc	ttc	ccg	gat	cag	gtg	gcc	atc	cag	1124	
Gly	Gln	Gly	Thr	Val	Phe	Asp	Ala	Phe	Pro	Asp	Gln	Val	Ala	Ile	Gln		
			325					330					335				
ctg	aat	gat	act	cac	cct	cgc	atc	gcg	atc	cct	gag	ctg	atg	agg	att	1172	
Leu	Asn	Asp	Thr	His	Pro	Arg	Ile	Ala	Ile	Pro	Glu	Leu	Met	Arg	Ile		
			340					345						350			

ttt gtg gat att gaa aaa ctg ccc tgg tcc aag gca tgg gag ctc aac	1220
Phe Val Asp Ile Glu Lys Leu Pro Trp Ser Lys Ala Trp Glu Leu Asn	
355 360 365	
cag aag acc ttc gcc tac acc aac cac aca gtg ctc ccg gaa gcc ctg	1268
Gln Lys Thr Phe Ala Tyr Thr Asn His Thr Val Leu Pro Glu Ala Leu	
370 375 380 385	
gag cgc tgg ccc gtg gac ctg gtg gag aag ctg ctc cct cga cat ttg	1316
Glu Arg Trp Pro Val Asp Leu Val Glu Lys Leu Leu Pro Arg His Leu	
390 395 400	
gaa atc att tat gag ata aat cag aag cat tta gat aga att gtg gcc	1364
Glu Ile Ile Tyr Glu Ile Asn Gln Lys His Leu Asp Arg Ile Val Ala	
405 410 415	
ttg ttt cct aaa gat gtg gac cct ctg aga agg atg tct ctg ata gaa	1412
Leu Phe Pro Lys Asp Val Asp Pro Leu Arg Arg Met Ser Leu Ile Glu	
420 425 430	
gag gaa gga agc aaa agg atc aac atg gcc cat ctc tgc att gtc ggt	1460
Glu Glu Gly Ser Lys Arg Ile Asn Met Ala His Leu Cys Ile Val Gly	
435 440 445	
tcc cat gct gtg aat ggc gtg gct aaa atc cac tca gac atc gtg aag	1508
Ser His Ala Val Asn Gly Val Ala Lys Ile His Ser Asp Ile Val Lys	
450 455 460 465	
act aaa gta ttc aag gac ttc agt gag cta gaa cct gac aag ttt cag	1556
Thr Lys Val Phe Lys Asp Phe Ser Glu Leu Glu Pro Asp Lys Phe Gln	
470 475 480	
aat aaa acc aat ggg atc act cca agg cgc tgg ctc cta ctc tgc aac	1604
Asn Lys Thr Asn Gly Ile Thr Pro Arg Arg Trp Leu Leu Leu Cys Asn	
485 490 495	
cca gga ctt gca gag ctc ata gca gag aaa att gga gaa gac tat gtg	1652
Pro Gly Leu Ala Glu Leu Ile Ala Glu Lys Ile Gly Glu Asp Tyr Val	
500 505 510	
aaa gac ctg agc cag ctg acg aag ctc cac agc ttc ctg ggt gat gat	1700
Lys Asp Leu Ser Gln Leu Thr Lys Leu His Ser Phe Leu Gly Asp Asp	
515 520 525	
gtc ttc ctc cgg gaa ctc gcc aag gtg aag cag gag aat aag ctg aag	1748
Val Phe Leu Arg Glu Leu Ala Lys Val Lys Gln Glu Asn Lys Leu Lys	
530 535 540 545	
ttt tct cag ttc ctg gag acg gag tac aaa gtg aag atc aac cca tcc	1796
Phe Ser Gln Phe Leu Glu Thr Glu Tyr Lys Val Lys Ile Asn Pro Ser	
550 555 560	
tcc atg ttt gat gtc cag gtg aag agg ata cat gag tac aag cga cag	1844
Ser Met Phe Asp Val Gln Val Lys Arg Ile His Glu Tyr Lys Arg Gln	
565 570 575	
ctc ttg aac tgt ctg cat gtg atc acg atg tac aac cgc att aag aaa	1892
Leu Leu Asn Cys Leu His Val Ile Thr Met Tyr Asn Arg Ile Lys Lys	
580 585 590	

gac cct aag aag tta ttc gtg cca agg aca gtt atc att ggt ggt aaa Asp Pro Lys Lys Leu Phe Val Pro Arg Thr Val Ile Ile Gly Gly Lys 595 600 605	1940
gct gcc cca gga tat cac atg gcc aaa atg atc ata aag ctg atc act Ala Ala Pro Gly Tyr His Met Ala Lys Met Ile Ile Lys Leu Ile Thr 610 615 620 625	1988
tca gtg gca gat gtg gtg aac aat gac cct atg gtt gga agc aag ttg Ser Val Ala Asp Val Val Asn Asn Asp Pro Met Val Gly Ser Lys Leu 630 635 640	2036
aaa gtc atc ttc ttg gag aac tac aga gta tct ctt gct gaa aaa gtc Lys Val Ile Phe Leu Glu Asn Tyr Arg Val Ser Leu Ala Glu Lys Val 645 650 655	2084
att cca gcc aca gat ctg tca gag cag att tcc act gca ggc acc gaa Ile Pro Ala Thr Asp Leu Ser Glu Gln Ile Ser Thr Ala Gly Thr Glu 660 665 670	2132
gcc tcg ggg aca ggc aat atg aag ttc atg cta aat ggg gcc cta act Ala Ser Gly Thr Gly Asn Met Lys Phe Met Leu Asn Gly Ala Leu Thr 675 680 685	2180
atc ggg acc atg gat ggg gcc aat gtg gaa atg gca gaa gaa gct ggg Ile Gly Thr Met Asp Gly Ala Asn Val Glu Met Ala Glu Glu Ala Gly 690 695 700 705	2228
gaa gag aac ctg ttc atc ttt ggc atg agc ata gat gat gtg gct gct Glu Glu Asn Leu Phe Ile Phe Gly Met Ser Ile Asp Asp Val Ala Ala 710 715 720	2276
ttg gac aag aaa ggg tac gag gca aaa gaa tac tat gag gca ctt cca Leu Asp Lys Lys Gly Tyr Glu Ala Lys Glu Tyr Tyr Glu Ala Leu Pro 725 730 735	2324
gag ctg aag ctg gtc att gat caa att gac aat ggc ttt ttt tct ccc Glu Leu Lys Leu Val Ile Asp Gln Ile Asp Asn Gly Phe Phe Ser Pro 740 745 750	2372
aag cag cct gac ctc ttc aaa gat atc atc aac atg cta ttt tat cat Lys Gln Pro Asp Leu Phe Lys Asp Ile Ile Asn Met Leu Phe Tyr His 755 760 765	2420
gac agg ttt aaa gtc ttt gca gac tac gaa gcc tat gtc aag tgt caa Asp Arg Phe Lys Val Phe Ala Asp Tyr Glu Ala Tyr Val Lys Cys Gln 770 775 780 785	2468
gat aaa gtg agt cag ctg tac atg aat cca aag gcc tgg aac aca atg Asp Lys Val Ser Gln Leu Tyr Met Asn Pro Lys Ala Trp Asn Thr Met 790 795 800	2516
gta ctc aaa aac ata gct gcc tcg ggg aaa ttc tcc agt gac cga aca Val Leu Lys Asn Ile Ala Ala Ser Gly Lys Phe Ser Ser Asp Arg Thr 805 810 815	2564
att aaa gaa tat gcc caa aac atc tgg aac gtg gaa cct tca gat cta Ile Lys Glu Tyr Ala Gln Asn Ile Trp Asn Val Glu Pro Ser Asp Leu	2612



820	825	830	
aag att tct cta tcc aat gaa tct aac aaa gtc aat gga aat tga			2657
Lys Ile Ser Leu Ser Asn Glu Ser Asn Lys Val Asn Gly Asn			
835	840	845	
actctacaat gtctctagaa aacatagctt cttactgaac ttgaacattt ttacaacatt			2717
cactgggtttt tggttttgta gctaataatc tataatagtt gagtatctct gggaatgggg			2777
agggaaatta tatgtaatag agcttaaaaa taaagtgtca atttccaagg a			2828
<210> 2			
<211> 21			
<212> DNA			
<213> Artificial Sequence			
<220>			
<223> PCR Primer			
<400> 2			
catgggccga acattacaga a			21
<210> 3			
<211> 21			
<212> DNA			
<213> Artificial Sequence			
<220>			
<223> PCR Primer			
<400> 3			
caagaccacc attgccaagt c			21
<210> 4			
<211> 27			
<212> DNA			
<213> Artificial Sequence			
<220>			
<223> PCR Probe			
<400> 4			
ctgtgatgag gccatttacc agcttgg			27
<210> 5			
<211> 19			
<212> DNA			
<213> Artificial Sequence			
<220>			
<223> PCR Primer			
<400> 5			
gaaggtgaag gtcggagtc			19

<210> 6  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR Primer

<400> 6  
 gaagatggtg atgggatttc 20

<210> 7  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> PCR Probe

<400> 7  
 caagcttccc gttctcagcc 20

<210> 8  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Antisense Oligonucleotide

<400> 8  
 ccgccccgcc gcgccaggag 20

<210> 9  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Antisense Oligonucleotide

<400> 9  
 cgggctgcgc agagagctgg 20

<210> 10  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Antisense Oligonucleotide

<400> 10

cagcggttcg cccatggctg

20

<210> 11  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Antisense Oligonucleotide

<400> 11  
 tctgtcagcg gttcgcccat

20

<210> 12  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Antisense Oligonucleotide

<400> 12  
 tgccacggttc tccacgcccc

20

<210> 13  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Antisense Oligonucleotide

<400> 13  
 cttgaccagc gtgaagtgc

20

<210> 14  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Antisense Oligonucleotide

<400> 14  
 gcgcgaagta gtagtcgcgg

20

<210> 15  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Antisense Oligonucleotide

CCDS-000000000

<400> 15  
tccagcgccc caccaggtgg 20

<210> 16  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Antisense Oligonucleotide

<400> 16  
cccatgtaaa attccagaga 20

<210> 17  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Antisense Oligonucleotide

<400> 17  
atattgcaga ccgaggttga 20

<210> 18  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Antisense Oligonucleotide

<400> 18  
ctcttctata tccaatccaa 20

<210> 19  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Antisense Oligonucleotide

<400> 19  
gcaggcagca agtctcccaa 20

<210> 20  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Antisense Oligonucleotide

<400> 20  
gccgtatcca taggctgcaa 20

<210> 21  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Antisense Oligonucleotide

<400> 21  
tacctgccat ccatctcgga 20

<210> 22  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Antisense Oligonucleotide

<400> 22  
gggcgggact tctcccaagg 20

<210> 23  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Antisense Oligonucleotide

<400> 23  
tcccgggtgtt ggtgtgttct 20

<210> 24  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Antisense Oligonucleotide

<400> 24  
ggtgttgaca gtgttattca 20

<210> 25  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
 <223> Antisense Oligonucleotide  
  
 <400> 25  
 tccaacatta aagtctctga 20  
  
 <210> 26  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Antisense Oligonucleotide  
  
 <400> 26  
 attgtcattg ggatagagga 20  
  
 <210> 27  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Antisense Oligonucleotide  
  
 <400> 27  
 tggagccaaa cttggaggct 20  
  
 <210> 28  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Antisense Oligonucleotide  
  
 <400> 28  
 ttctggttga gctcccatgc 20  
  
 <210> 29  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Antisense Oligonucleotide  
  
 <400> 29  
 acgggccagc gctccagggc 20  
  
 <210> 30  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Antisense Oligonucleotide  
  
 <400> 30  
 atgcttctga tttatctcat 20  
  
 <210> 31  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Antisense Oligonucleotide  
  
 <400> 31  
 atcagagaca tccttctcag 20  
  
 <210> 32  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Antisense Oligonucleotide  
  
 <400> 32  
 cacagcatgg gaaccgacaa 20  
  
 <210> 33  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Antisense Oligonucleotide  
  
 <400> 33  
 gaagtccttg aatacttttag 20  
  
 <210> 34  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Antisense Oligonucleotide  
  
 <400> 34  
 ctgcaagtcc tgggttgacag 20  
  
 <210> 35  
 <211> 20  
 <212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 35

atcacccagg aagctgtgga

20

<210> 36

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 36

aggatggggtt gatcttcact

20

<210> 37

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 37

acagttcaag agctgtcgct

20

<210> 38

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 38

cagctttacc accaatgata

20

<210> 39

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 39

ttccaaccat agggtcattg

20

<210> 40

<211> 20



<212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Antisense Oligonucleotide  
  
 <400> 40  
 atctgtggct ggaatgactt 20  
  
  
 <210> 41  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Antisense Oligonucleotide  
  
 <400> 41  
 tcatattgcc tgtccccgag 20  
  
  
 <210> 42  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Antisense Oligonucleotide  
  
 <400> 42  
 ccacattggc cccatccatg 20  
  
  
 <210> 43  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Antisense Oligonucleotide  
  
 <400> 43  
 atgctcatgc caaagatgaa 20  
  
  
 <210> 44  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Antisense Oligonucleotide  
  
 <400> 44  
 agtattcttt tgctcgtac 20  
  
  
 <210> 45

20

20

20

ANTISENSE MODULATION OF LIVER GLYCOGEN PHOSPHORYLASE  
EXPRESSION

FIELD OF THE INVENTION

5 The present invention provides compositions and methods for modulating the expression of liver glycogen phosphorylase. In particular, this invention relates to antisense compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding human  
10 liver glycogen phosphorylase. Such oligonucleotides have been shown to modulate the expression of liver glycogen phosphorylase.

BACKGROUND OF THE INVENTION

There are several mechanisms in place for the  
15 homeostatic regulation of biological processes, and balanced energy metabolism is critical to all of these mechanisms. In higher organisms energy stores are in the form of glycogen and upon energy deficit these stores are mobilized through enzymatic digestion to glucose-1-  
20 phosphate by the glycogen phosphorylase family of proteins.

Mammalian glycogen phosphorylases comprise a family of three isozymes which are distinguished by their electrophoretic mobilities, immunological properties and tissue-specific distribution. Each isozyme is encoded by a  
25 different gene, and these genes have been denoted PYGL, PYGM and PYGB, for liver, muscle and brain isoforms, respectively (Newgard et al., *Crit. Rev. Biochem. Mol. Biol.*, 1989, 24, 69-99). The primary control however, common to all isozymes, is the phosphorylation of the  
30 inactive state, (b), to the active phosphorylated state, (a). This phosphorylation on serine-14 stabilizes the subunits of the homodimer and alters the binding sites for allosteric effectors and substrates (Sprang et al., *Nature*, 1988, 336, 215-221).

-2-

Liver glycogen phosphorylase (also known as 1,4- $\alpha$ -D-glucan:orthophosphate  $\alpha$ -D-glucosyltransferase, glycogen phosphorylase (liver), EC 2.4.1.1 and HLGP<sub>a</sub>, for human liver glycogen phosphorylase a) is the enzyme which

5 catalyzes the degradation of stored glycogen in the liver to glucose-1-phosphate by the cleavage of  $\alpha$ -1,4-glycosidic bonds and therefore plays a critical role in carbohydrate metabolism and blood glucose homeostasis (Newgard et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1986, 83, 8132-8136). The

10 activity of liver glycogen phosphorylase is tightly regulated requiring the presence of a cofactor, pyridoxal phosphate, and involving allosteric mechanisms which include activation by AMP and glycogen binding and inhibition by glucose and glucose-6-phosphate binding. The

15 enzyme is also regulated through phosphorylation by phosphorylase kinase which activates the homodimer (Keppens et al., *Hepatology*, 1993, 17, 610-614).

The gene for liver glycogen phosphorylase (PYGL) has been mapped to chromosome 14 and mutations in this gene

20 give rise to glycogen storage disease type VI (GSD VI) or Hers Disease, a group of disorders that cause hepatomegaly and hypoglycemia (Burwinkel et al., *Am. J. Hum. Genet.*, 1998, 62, 785-791; Chang et al., *Hum. Mol. Genet.*, 1998, 7, 865-870; Newgard et al., *Am. J. Hum. Genet.*, 1987, 40, 351-

25 364). These mutations consist of two splice-site mutations which result in aberrant exon retention and exon skipping and two missense mutations which produce nonconservative replacements of amino acids that are normally conserved in all eukaryotes.

30 To date, two types of inhibitors targeting glycogen phosphorylase function have been reported. These involved the use of glucose analogs containing multiple polar groups which bind near the active site of the protein (Lundgren et al., 1997; Lundgren and Kirk, 1995) and caffeine and other

heteroaromatic analogs which bind at the purine inhibitory site (Kasvinsky et al., *Can. J. Biochem.*, 1981, 59, 387-395; Kasvinsky et al., *J. Biol. Chem.*, 1978, 253, 3343-3351; Kasvinsky et al., *J. Biol. Chem.*, 1978, 253, 9102-9106). However, none of these compounds have been shown to be orally active, limiting their utility.

Recently, the discovery of an orally active compound, CP-91149 and derivatives thereof, that lowers plasma glucose levels in an animal model of type 2 diabetes was reported (Hoover et al., *J. Med. Chem.*, 1998, 41, 2934-2938; Martin et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1998, 95, 1776-1781). This indole-containing compound was shown to inhibit glycogenolysis in diabetic ob/ob mice, and in rat and human liver cells by inhibiting liver glycogen phosphorylase. It is believed that inhibition of glycogenolysis will be of therapeutic benefit in the treatment of diabetes, particularly type II diabetes.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of glycogen phosphorylase expression.

#### SUMMARY OF THE INVENTION

The present invention is directed to antisense compounds, particularly oligonucleotides, which are targeted to a nucleic acid encoding liver glycogen phosphorylase, and which modulate the expression of liver glycogen phosphorylase. Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided. Further provided are methods of modulating the expression of liver glycogen phosphorylase in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further

-4-

provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of liver glycogen phosphorylase by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding liver glycogen phosphorylase, ultimately modulating the amount of liver glycogen phosphorylase produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding liver glycogen phosphorylase. As used herein, the terms "target nucleic acid" and "nucleic acid encoding liver glycogen phosphorylase" encompass DNA encoding liver glycogen phosphorylase, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of liver glycogen phosphorylase. In the context of the present invention, "modulation" means either an increase

-5-

(stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

5 It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose  
10 function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is  
15 a nucleic acid molecule encoding liver glycogen phosphorylase. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the  
20 protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is  
25 typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence  
30 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in  
35 eukaryotes) or formylmethionine (in prokaryotes). It is

-6-

also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding liver glycogen phosphorylase, regardless of the sequence(s) of such codons.

It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region (3'UTR), known in



-7-

the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap.

10 The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

15 regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

20 overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

25 targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

30 effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through

35 thymine are complementary nucleobases which pair through

the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to

distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also  
5 harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous  
10 clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

15 In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and  
20 covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example,  
25 enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other  
30 oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides).

35 Particularly preferred antisense compounds are antisense

-10-

oligonucleotides, even more preferably those comprising from about 12 to about 25 nucleobases. As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base.

5 The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar,

10 the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this

15 linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The

20 normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural

25 internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as

30 sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates,

35 phosphorodithioates, phosphotriesters, aminoalkyl-

-11-

phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, 5 thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 10 5'-2'. Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 15 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, certain of 20 which are commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside 25 linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane 30 backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide

backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, 1991, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH<sub>2</sub>-NH-O-CH<sub>2</sub>-, -CH<sub>2</sub>-N(CH<sub>3</sub>)-O-CH<sub>2</sub>- [known as a

methylene (methylimino) or MMI backbone],  $-\text{CH}_2-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-$ ,  
 $-\text{CH}_2-\text{N}(\text{CH}_3)-\text{N}(\text{CH}_3)-\text{CH}_2-$  and  $-\text{O}-\text{N}(\text{CH}_3)-\text{CH}_2-\text{CH}_2-$  [wherein the  
native phosphodiester backbone is represented as  $-\text{O}-\text{P}-\text{O}-\text{CH}_2-$   
] of the above referenced U.S. patent 5,489,677, and the  
5 amide backbones of the above referenced U.S. patent  
5,602,240. Also preferred are oligonucleotides having  
morpholino backbone structures of the above-referenced U.S.  
patent 5,034,506.

Modified oligonucleotides may also contain one or more  
10 substituted sugar moieties. Preferred oligonucleotides  
comprise one of the following at the 2' position: OH; F; O-  
, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-  
alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and  
alkynyl may be substituted or unsubstituted  $\text{C}_1$  to  $\text{C}_{10}$  alkyl  
15 or  $\text{C}_2$  to  $\text{C}_{10}$  alkenyl and alkynyl. Particularly preferred are  
 $\text{O}[(\text{CH}_2)_n\text{O}]_m\text{CH}_3$ ,  $\text{O}(\text{CH}_2)_n\text{OCH}_3$ ,  $\text{O}(\text{CH}_2)_n\text{NH}_2$ ,  $\text{O}(\text{CH}_2)_n\text{CH}_3$ ,  $\text{O}(\text{CH}_2)_n\text{ONH}_2$ ,  
and  $\text{O}(\text{CH}_2)_n\text{ON}[(\text{CH}_2)_n\text{CH}_3]_2$ , where n and m are from 1 to about  
10. Other preferred oligonucleotides comprise one of the  
following at the 2' position:  $\text{C}_1$  to  $\text{C}_{10}$  lower alkyl,  
20 substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-  
aralkyl, SH,  $\text{SCH}_3$ , OCN, Cl, Br, CN,  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  $\text{SOCH}_3$ ,  $\text{SO}_2\text{CH}_3$ ,  
 $\text{ONO}_2$ ,  $\text{NO}_2$ ,  $\text{N}_3$ ,  $\text{NH}_2$ , heterocycloalkyl, heterocycloalkaryl,  
aminoalkylamino, polyalkylamino, substituted silyl, an RNA  
cleaving group, a reporter group, an intercalator, a group  
25 for improving the pharmacokinetic properties of an  
oligonucleotide, or a group for improving the  
pharmacodynamic properties of an oligonucleotide, and other  
substituents having similar properties. A preferred  
modification includes 2'-methoxyethoxy ( $2'-\text{O}-\text{CH}_2\text{CH}_2\text{OCH}_3$ , also  
30 known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al.,  
*Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy  
group. A further preferred modification includes 2'-  
dimethylaminoethoxy, i.e., a  $\text{O}(\text{CH}_2)_2\text{ON}(\text{CH}_3)_2$  group, also  
known as 2'-DMAOE, as described in examples hereinbelow,  
35 and 2'-dimethylaminoethoxyethoxy (also known in the art as

-14-

2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>2</sub>)<sub>2</sub>, also described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH<sub>3</sub>), 2'-aminopropoxy (2'-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and



-15-

guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, certain of which are commonly owned with the instant application, and each of

-16-

which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

5 Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but  
10 are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*,  
15 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmooaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et  
20 al., *FEBS Lett.*, 1990, 259, 327-330; Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al.,  
25 *Tetrahedron Lett.*, 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654),  
30 a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937).

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but

-17-

are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105;  
5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717,  
5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802;  
5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718;  
5 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779;  
4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582;  
4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830;  
5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506;  
5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241,  
10 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667;  
5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481;  
5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and  
5,688,941, certain of which are commonly owned with the  
instant application, and each of which is herein  
15 incorporated by reference.

It is not necessary for all positions in a given  
compound to be uniformly modified, and in fact more than  
one of the aforementioned modifications may be incorporated  
in a single compound or even at a single nucleoside within  
20 an oligonucleotide. The present invention also includes  
antisense compounds which are chimeric compounds.  
"Chimeric" antisense compounds or "chimeras," in the  
context of this invention, are antisense compounds,  
particularly oligonucleotides, which contain two or more  
25 chemically distinct regions, each made up of at least one  
monomer unit, i.e., a nucleotide in the case of an  
oligonucleotide compound. These oligonucleotides typically  
contain at least one region wherein the oligonucleotide is  
modified so as to confer upon the oligonucleotide increased  
30 resistance to nuclease degradation, increased cellular  
uptake, and/or increased binding affinity for the target  
nucleic acid. An additional region of the oligonucleotide  
may serve as a substrate for enzymes capable of cleaving  
RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is  
35 a cellular endonuclease which cleaves the RNA strand of an

-18-

RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of

biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other

5 molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such  
10 uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.:

5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291;  
5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330;  
4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170;  
15 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978;  
5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259;  
5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The antisense compounds of the invention encompass any  
20 pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the  
25 disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is  
30 prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE  
35 [(S-acetyl-2-thioethyl) phosphate] derivatives according to

the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to  
5 physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are  
10 formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are  
N,N'-dibenzylethylenediamine, chloroprocaine, choline,  
15 diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a  
20 sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms  
25 somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an  
30 acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable  
35 salts are well known to those skilled in the art and

-21-

include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfoic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts

-22-

formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of liver glycogen phosphorylase is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding liver glycogen phosphorylase, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding liver glycogen phosphorylase can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the



oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of liver glycogen phosphorylase in a sample may also be prepared.

5 The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or  
10 systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by  
15 nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or  
20 intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments,  
25 lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

30 Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not  
5 limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may  
10 be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit  
15 dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared  
20 by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be  
25 formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions  
30 may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the  
35 pharmaceutical compositions may be formulated and used as

foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

#### Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1  $\mu\text{m}$  in diameter. (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting

composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion.

Emulsifiers may broadly be classified into four categories:

synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and

5 Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are

10 typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified  
15 into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

20 Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as  
25 anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as  
30 bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also  
35 included in emulsion formulations and contribute to the

properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers*

and *Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant,

- 5 cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules
- 10 (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how

15 to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York,

20 N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

- 25 Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol
- 30 monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain



alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385; Ho et al., *J. Pharm. Sci.*, 1996, 85, 138-143). Often microemulsions may form spontaneously when their components

-32-

are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

#### Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term

-33-

"liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs.

There is growing evidence that for topical administration, liposomes present several advantages over other

5 formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into  
10 the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been  
15 administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable  
20 complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res.*  
25 *Commun.*, 1987, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is  
30 entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled*  
35 *Release*, 1992, 19, 269-274).

-35-

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, 1992, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of

-36-

cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, 1994, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to

5 liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming  
10 lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside  $G_{M1}$ , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art  
15 that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES)  
20 (Allen et al., *FEBS Letters*, 1987, 223, 42; Wu et al., *Cancer Research*, 1993, 53, 3765). Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, 1987, 507, 64) reported the ability of  
25 monosialoganglioside  $G_{M1}$ , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, 1988, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et  
30 al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside  $G_{M1}$  or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising

-37-

1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C<sub>12</sub>15G, that contains a PEG moiety. Illum et al. (*FEBS Lett.*, 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov et al. (*FEBS Lett.*, 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO

96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

- 5 A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and
- 10 asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense
- 15 oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly

20 deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their

25 targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of

30 serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The

35 most common way of classifying and ranking the properties



of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The

-40-

quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

#### Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical

-41-

entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of  
5 oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug*  
10 *Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example,  
15 oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-  
20 dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C<sub>1-10</sub> alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in*  
25 *Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

30 Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp.

-42-

934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydrofusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579-583).

25       Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating

agents (Jarrett, *J. Chromatogr.*, 1993, 618, 315-339).  
Chelating agents of the invention include but are not  
limited to disodium ethylenediaminetetraacetate (EDTA),  
citric acid, salicylates (e.g., sodium salicylate, 5-  
5 methoxysalicylate and homovanilate), N-acyl derivatives of  
collagen, laureth-9 and N-amino acyl derivatives of beta-  
diketones (enamines) (Lee et al., *Critical Reviews in*  
*Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi,  
*Critical Reviews in Therapeutic Drug Carrier Systems*, 1990,  
10 7, 1-33; Buur et al., *J. Control Rel.*, 1990, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-  
chelating non-surfactant penetration enhancing compounds  
can be defined as compounds that demonstrate insignificant  
15 activity as chelating agents or as surfactants but that  
nonetheless enhance absorption of oligonucleotides through  
the alimentary mucosa (Muranishi, *Critical Reviews in*  
*Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). This  
class of penetration enhancers include, for example,  
20 unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-  
alkanone derivatives (Lee et al., *Critical Reviews in*  
*Therapeutic Drug Carrier Systems*, 1991, page 92); and non-  
steroidal anti-inflammatory agents such as diclofenac  
sodium, indomethacin and phenylbutazone (Yamashita et al.,  
25 *J. Pharm. Pharmacol.*, 1987, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the  
cellular level may also be added to the pharmaceutical and  
other compositions of the present invention. For example,  
cationic lipids, such as lipofectin (Junichi et al, U.S.  
30 Patent No. 5,705,188), cationic glycerol derivatives, and  
polycationic molecules, such as polylysine (Lollo et al.,  
PCT Application WO 97/30731), are also known to enhance the  
cellular uptake of oligonucleotides.

-44-

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

## 5 Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation.

10 The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-  
20 4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao et al., *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura et al., *Antisense & Nucl. Acid Drug Dev.*, 1996, 6, 177-183).

## Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in  
35 mind, so as to provide for the desired bulk, consistency,

etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like. Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol,

-46-

polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

#### Other Components

5 The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible,  
10 pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as  
15 dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations  
20 can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact  
25 with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

30 Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents  
35 include, but are not limited to, anticancer drugs such as



daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine  
5 (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 1206-1228). Anti-inflammatory  
10 drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck*  
15 *Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

20 In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples  
25 of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity  
30 and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in  
35 the body of the patient. Persons of ordinary skill can

easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on  $EC_{50}$ s found to be

5 effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate  
10 repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the  
15 oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its preferred  
20 embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

#### EXAMPLES

##### Example 1

#### 25 Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2'-alkoxy amidites

2'-Deoxy and 2'-methoxy beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling  
30 VA). Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the

wait step after pulse delivery of tetrazole and base was increased to 360 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., *Nucleic Acids Research*, 1993, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA).

#### 2'-Fluoro amidites

##### 2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, 1993, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S<sub>N</sub>2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

##### 2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected

arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups.

Standard methodologies were used to obtain the 5'-DMT- and  
5 5'-DMT-3'-phosphoramidites.

#### 2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was  
10 treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

#### 2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via  
15 amination of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

#### 2'-O-(2-Methoxyethyl) modified amidites

20 2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

#### 2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]

25 5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved  
30 carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the

residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C).

#### 2'-O-Methoxyethyl-5-methyluridine

2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH<sub>3</sub>CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH<sub>2</sub>Cl<sub>2</sub>/acetone/MeOH (20:5:3) containing 0.5% Et<sub>3</sub>NH. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions.

#### 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278

M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with

5 CH<sub>3</sub>CN (200 mL). The residue was dissolved in CHCl<sub>3</sub> (1.5 L) and extracted with 2x500 mL of saturated NaHCO<sub>3</sub> and 2x500 mL of saturated NaCl. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated. 275 g of residue was obtained.

The residue was purified on a 3.5 kg silica gel column, 10 packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et<sub>3</sub>NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

15 3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and 20 acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture 25 evaporated at 35°C. The residue was dissolved in CHCl<sub>3</sub> (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl<sub>3</sub>. The combined organics were dried with sodium sulfate and 30 evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions.

**3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine**

A first solution was prepared by dissolving 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH<sub>3</sub>CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH<sub>3</sub>CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl<sub>3</sub> was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO<sub>3</sub> and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound.

**2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH<sub>4</sub>OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH<sub>3</sub> gas was added and the vessel heated to 100°C for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over

sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

**N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

5        2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was  
10 evaporated and the residue azeotropered with MeOH (200 mL). The residue was dissolved in CHCl<sub>3</sub> (700 mL) and extracted with saturated NaHCO<sub>3</sub> (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO<sub>4</sub> and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica  
15 column using EtOAc/hexane (1:1) containing 0.5% Et<sub>3</sub>NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

**N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite**

20        N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting  
25 mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO<sub>3</sub> (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes were back-extracted with CH<sub>2</sub>Cl<sub>2</sub> (300 mL), and the extracts were  
30 combined, dried over MgSO<sub>4</sub> and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound.



2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

5'-O-tert-Butyldiphenylsilyl-O<sup>2</sup>-2'-anhydro-5-methyluridine

O<sup>2</sup>-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

**5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine**

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

**2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine**

**5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-**

-57-

methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over  $P_2O_5$  under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylidiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry  $CH_2Cl_2$  (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate was washed with ice cold  $CH_2Cl_2$  and the combined organic phase was washed with water, brine and dried over anhydrous  $Na_2SO_4$ . The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5'-O-tert-butylidiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine as white foam (1.95 g, 78%).

**5'-O-tert-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine**

5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol)

5 was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the  
10 reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). Aqueous NaHCO<sub>3</sub> solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, evaporated to  
15 dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol)  
20 was added and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO<sub>3</sub> (25mL) solution was added and extracted with ethyl acetate  
25 (2x25mL). Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and evaporated to dryness. The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to get 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-dimethylaminoxyethyl]-5-methyluridine as a white foam  
30 (14.6g, 80%).

**2'-O-(dimethylaminoxyethyl)-5-methyluridine**

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was  
35 then added to 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N-

dimethylaminoxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in  $\text{CH}_2\text{Cl}_2$ ). Solvent was removed under vacuum and the residue placed on a flash column and  
5 eluted with 10% MeOH in  $\text{CH}_2\text{Cl}_2$  to get 2'-O-(dimethylaminoxyethyl)-5-methyluridine (766mg, 92.5%).

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine

2'-O-(dimethylaminoxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over  $\text{P}_2\text{O}_5$  under high vacuum overnight at  
10 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2.60mmol) was added to the mixture and the reaction mixture  
15 was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in  $\text{CH}_2\text{Cl}_2$  (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

20 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL).  
25 To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over  $\text{P}_2\text{O}_5$  under high vacuum overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N<sup>1</sup>,N<sup>1</sup>-tetraisopropylphosphoramidite (2.12mL, 6.08mmol)  
30 was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5%

aqueous NaHCO<sub>3</sub> (40mL). Ethyl acetate layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

**2'-(Aminooxyethoxy) nucleoside amidites**

2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-

diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

**2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside**

**5 amidites**

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH<sub>2</sub>-O-CH<sub>2</sub>-N(CH<sub>2</sub>)<sub>2</sub>, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared  
10 similarly.

**2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL  
15 bomb. Hydrogen gas evolves as the solid dissolves. O<sup>2</sup>-, 2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude  
20 solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried  
25 over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a  
30 white solid.

**5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine**

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8

mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with  $\text{CH}_2\text{Cl}_2$  (2x200 mL). The combined  $\text{CH}_2\text{Cl}_2$  layers are washed with saturated  $\text{NaHCO}_3$  solution, followed by saturated  $\text{NaCl}$  solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using  $\text{MeOH}:\text{CH}_2\text{Cl}_2:\text{Et}_3\text{N}$  (20:1, v/v, with 1% triethylamine) gives the title compound.

5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyluridine (2.17 g, 3 mmol) dissolved in  $\text{CH}_2\text{Cl}_2$  (20 mL) under an atmosphere of argon. The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

## Example 2

### Oligonucleotide synthesis

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and



deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as

5 described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

10 3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent  
15 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

20 3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by  
25 reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

### Example 3

#### 30 Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino  
35 linked oligonucleosides, also identified as amide-3 linked

oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are  
5 prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and  
10 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

#### Example 4

#### 15 PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*,  
20 1996, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

#### Example 5

#### Synthesis of Chimeric Oligonucleotides

25 Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked  
30 nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped

-65-

oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric

#### Phosphorothioate Oligonucleotides

5 Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated  
10 synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s  
15 repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia  
20 for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced  
25 to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-

30 (Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl

-66-

chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl)

5 Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester)--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester]

chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with  
10 the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dihydro-2H-benzothio-1,1-dioxide (Beaucage  
15 Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent  
20 5,623,065, herein incorporated by reference.

#### Example 6

##### Oligonucleotide Isolation

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated  
25 ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and  
30 judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by <sup>31</sup>P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as

-67-

described by Chiang et al., *J. Biol. Chem.* 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

#### 5 Example 7

##### Oligonucleotide Synthesis - 96 Well Plate Format

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzothiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-cyanoethyl-diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated  $\text{NH}_4\text{OH}$  at elevated temperature ( $55-60^\circ\text{C}$ ) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

#### Example 8

##### 30 Oligonucleotide Analysis - 96 Well Plate Format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in

either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds  
5 utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

#### 10 Example 9

##### Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at  
15 measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following four cell types are provided for illustrative purposes, but other cell types can be routinely used.

##### 20 T-24 cells:

The transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life  
25 Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and  
30 dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates

-69-

and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

5       The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

15

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

25       Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates,

-70-

wells were washed once with 200  $\mu$ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130  $\mu$ L of OPTI-MEM™-1 containing 3.75  $\mu$ g/mL LIPOFECTIN™ (Gibco BRL) and the desired oligonucleotide at a final concentration of 5 150 nM. After 4 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16 hours after oligonucleotide treatment.

#### Example 10

#### Analysis of oligonucleotide inhibition of liver glycogen 10 phosphorylase expression

Antisense modulation of liver glycogen phosphorylase expression can be assayed in a variety of ways known in the art. For example, liver glycogen phosphorylase mRNA levels can be quantitated by, e.g., Northern blot analysis, 15 competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in* 20 *Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in* 25 *Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Other methods of PCR are 30 also known in the art.

Liver glycogen phosphorylase protein levels can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell



-71-

sorting (FACS). Antibodies directed to liver glycogen phosphorylase can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via  
5 conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal  
10 antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al.,  
15 *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-  
20 10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

## 25 **Example 11**

### **Poly(A)+ mRNA isolation**

Poly(A)+ mRNA was isolated according to Miura et al., *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example,  
30 Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200  $\mu$ L cold PBS. 60  $\mu$ L lysis buffer (10 mM

-72-

Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55  $\mu$ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200  $\mu$ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60  $\mu$ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

#### Example 12

##### Total RNA Isolation

Total mRNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200  $\mu$ L cold PBS. 100  $\mu$ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100  $\mu$ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of

-73-

15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the  
5 QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 µL water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 µL water.

10 The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are  
15 carried out.

#### **Example 13**

#### **Real-time Quantitative PCR Analysis of liver glycogen phosphorylase mRNA Levels**

Quantitation of liver glycogen phosphorylase mRNA  
20 levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput  
25 quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by  
30 including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE or FAM, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City,  
35 CA) is attached to the 5' end of the probe and a quencher

-74-

dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding 25  $\mu$ L PCR cocktail (1x TAQMAN™ buffer A, 5.5 mM  $MgCl_2$ , 300  $\mu$ M each of dATP, dCTP and dGTP, 600  $\mu$ M of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25  $\mu$ L poly(A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C.

Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension). Liver glycogen phosphorylase probes and primers were designed to hybridize

-75-

to the human liver glycogen phosphorylase sequence, using published sequence information (GenBank accession number M14636, incorporated herein as SEQ ID NO:1).

For liver glycogen phosphorylase the PCR primers were:

- 5 forward primer: CATGGGCCGAACATTACAGAA (SEQ ID NO: 2)  
reverse primer: CAAGACCACCATTGCCAAGTC (SEQ ID NO: 3) and  
the PCR probe was: FAM-CTGTGATGAGGCCATTTACCAGCTTGG-TAMRA  
(SEQ ID NO: 4) where FAM (PE-Applied Biosystems, Foster  
City, CA) is the fluorescent reporter dye) and TAMRA (PE-  
10 Applied Biosystems, Foster City, CA) is the quencher dye.

For GAPDH the PCR primers were:

- forward primer: GAAGGTGAAGGTCGAGTC (SEQ ID NO: 5)  
reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 6) and the  
PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ  
15 ID NO: 7) where JOE (PE-Applied Biosystems, Foster City,  
CA) is the fluorescent reporter dye) and TAMRA (PE-Applied  
Biosystems, Foster City, CA) is the quencher dye.

#### Example 14

#### 20 Northern blot analysis of liver glycogen phosphorylase mRNA levels

- Eighteen hours after antisense treatment, cell  
monolayers were washed twice with cold PBS and lysed in 1  
mL RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA  
was prepared following manufacturer's recommended  
25 protocols. Twenty micrograms of total RNA was fractionated  
by electrophoresis through 1.2% agarose gels containing  
1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc.  
Solon, OH). RNA was transferred from the gel to HYBOND™-N+  
nylon membranes (Amersham Pharmacia Biotech, Piscataway,  
30 NJ) by overnight capillary transfer using a  
Northern/Southern Transfer buffer system (TEL-TEST "B"  
Inc., Friendswood, TX). RNA transfer was confirmed by UV  
visualization. Membranes were fixed by UV cross-linking  
using a STRATALINKER™ UV Crosslinker 2400 (Stratagene,  
35 Inc, La Jolla, CA).

Membranes were probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer's recommendations for stringent conditions with a liver glycogen phosphorylase specific probe prepared by PCR using the forward primer CATGGGCCGAACATTACAGAA (SEQ ID NO: 2) and the reverse primer CAAGACCACCATTTGCCAAGTC (SEQ ID NO: 3). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA). Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

#### Example 15

##### **Antisense inhibition of liver glycogen phosphorylase expression- phosphorothioate oligodeoxynucleotides**

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human liver glycogen phosphorylase RNA, using published sequences (GenBank accession number M14636, incorporated herein as SEQ ID NO: 1). The oligonucleotides are shown in Table 1. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. M14636), to which the oligonucleotide binds. All compounds in Table 1 are oligodeoxynucleotides with phosphorothioate backbones (internucleoside linkages) throughout. The compounds were analyzed for effect on liver glycogen phosphorylase mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

-77-

Table 1

Inhibition of liver glycogen phosphorylase mRNA levels by  
phosphorothioate oligodeoxynucleotides

5	ISIS#	REGION	TARGET	SEQUENCE	%	SEQ ID
			SITE		Inhibition	NO.
	104049	5' UTR	9	cgcggccgcgcgcgcaggag	0	8
	104050	5' UTR	71	cgggctgcgcagagagctgg	13	9
	104051	Start Codon	109	cagcgggttcgcccattggctg	2	10
	104052	Start Codon	114	tctgtcagcgggttcgcccatt	31	11
10	104053	Coding	172	tgccacgttctccacgcca	82	12
	104054	Coding	220	cttgaccagcgtgaagtgc	52	13
	104055	Coding	260	gcgcgaagtagtagtcgcgg	20	14
	104056	Coding	299	tccagcgcggccaccagggtg	56	15
	104057	Coding	372	cccatgtaaaattccagaga	56	16
15	104058	Coding	415	attttgcagaccgaggttga	69	17
	104059	Coding	460	ctcttctatatccaatccaa	37	18
	104060	Coding	523	gcaggcagcaagtctcccaa	71	19
	104061	Coding	571	gccgtatccataggctgcaa	0	20
	104062	Coding	625	tacctgccatccatctcgga	85	21
20	104063	Coding	678	gggcgggacttctcccaagg	21	22
	104064	Coding	734	tcccgggtgttggtgtgttct	37	23
	104065	Coding	817	ggtgttgacagtgttattca	44	24
	104066	Coding	877	tccaacattaaagtctctga	38	25
	104067	Coding	949	attgtcattgggatagagga	51	26
25	104068	Coding	1052	tggagccaaacttggaggct	68	27
	104069	Coding	1206	ttctgggttgagctcccatgc	48	28
	104070	Coding	1263	acggggccagcgcctccagggc	53	29
	104071	Coding	1327	atgcttctgatttatctcat	51	30
	104072	Coding	1389	atcagagacatccttctcag	67	31
30	104073	Coding	1453	cacagcatgggaaccgacaa	85	32
	104074	Coding	1510	gaagtccttgaatacttttag	60	33
	104075	Coding	1598	ctgcaagtcctgggttgag	51	34
	104076	Coding	1678	atcaccaggaagctgtgga	69	35
	104077	Coding	1778	aggatgggttgatcttctact	61	36
35	104078	Coding	1837	acagttcaagagctgtcgct	61	37
	104079	Coding	1925	cagctttaccaccaatgata	71	38
	104080	Coding	2009	ttccaaccatagggtcattg	73	39
	104081	Coding	2080	atctgtggctggaatgactt	21	40
	104082	Coding	2135	tcatattgcctgtccccgag	82	41
40	104083	Coding	2189	ccacattggccccatccatg	81	42
	104084	Coding	2241	atgctcatgccaaagatgaa	2	43
	104085	Coding	2291	agtattcttttgcctcgtag	79	44
	104086	Coding	2337	ttgtcaatttgatcaatgac	38	45

-78-

104087 Coding	2403	tcatgataaaatagcatggtt	0	46
104088 3' UTR	2758	ccccattcccagagatactc	68	47

As shown in Table 1, SEQ ID NOS 11, 12, 13, 15, 16, 17, 18, 19, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41, 42, 44, 45 and 47 demonstrated at least 30% inhibition of liver glycogen phosphorylase expression in this assay and are therefore preferred.

**Example 16:**

### 10 Antisense inhibition of liver glycogen phosphorylase expression- phosphorothioate 2'-MOE gapmer oligonucleotides

In accordance with the present invention, a second series of oligonucleotides targeted to human liver glycogen phosphorylase were synthesized. The oligonucleotide sequences are shown in Table 2. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. M14636), to which the oligonucleotide binds.

All compounds in Table 2 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. Cytidine residues in the 2'-MOE wings are 5-methylcytidines.

Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from two experiments. If present, "N.D." indicates "no data".



Table 2

Inhibition of liver glycogen phosphorylase mRNA levels by  
chimeric phosphorothioate oligonucleotides having 2'-MOE  
wings and a deoxy gap

5	ISIS#	REGION	TARGET SITE	SEQUENCE	% Inhibition	SEQ ID NO.
	104089	5' UTR	9	ccgccccgcgcgcgcaggag	0	8
	104090	5' UTR	71	cgggctgcgcagagagctgg	61	9
10	104091	Start Codon	109	cagcggttcgcccatggctg	20	10
	104092	Start Codon	114	tctgtcagcggttcgcccat	23	11
	104093	Coding	172	tgccacgttctccacgcccc	90	12
	104094	Coding	220	cttgaccagcgtgaagtgca	88	13
	104095	Coding	260	gcgcgaagtagtagtcgcgg	76	14
15	104096	Coding	299	tccagcgcgccaccagggtg	87	15
	104097	Coding	372	cccatgtaaaattccagaga	98	16
	104098	Coding	415	attttgcagaccgaggttga	94	17
	104099	Coding	460	ctcttctatatccaatccaa	71	18
	104100	Coding	523	gcaggcagcaagtctcccaa	57	19
20	104101	Coding	571	gcggtatccataggctgcaa	97	20
	104102	Coding	625	tacctgccatccatctcgga	89	21
	104103	Coding	678	gggcgggacttctcccaagg	79	22
	104104	Coding	734	tcccggtgttggtgtgttct	89	23
	104105	Coding	817	ggtgttgacagtgttattca	95	24
25	104106	Coding	877	tccaacattaaagtctctga	77	25
	104107	Coding	949	attgtcattgggatagagga	92	26
	104108	Coding	1052	tggagccaaacttggaggct	77	27
	104109	Coding	1206	ttctggttgagctcccatgc	48	28
	104110	Coding	1263	acggggccagcgtccagggc	82	29
30	104111	Coding	1327	atgcttctgatttatctcat	83	30
	104112	Coding	1389	atcagagacatccttctcag	96	31
	104113	Coding	1453	cacagcatgggaaccgacaa	88	32
	104114	Coding	1510	gaagtccttgaatacttttag	86	33
	104115	Coding	1598	ctgcaagtcctgggttgag	74	34
35	104116	Coding	1678	atcaccaggaagctgtgga	70	35
	104117	Coding	1778	aggatgggttgatcttcaact	70	36
	104118	Coding	1837	acagttcaagagctgtcgct	85	37
	104119	Coding	1925	cagctttaccaccaatgata	58	38
	104120	Coding	2009	ttccaaccatagggtcattg	86	39
40	104121	Coding	2080	atctgtggctggaatgactt	40	40
	104122	Coding	2135	tcatattgcctgtccccgag	49	41
	104123	Coding	2189	ccacattggcccatccatg	90	42
	104124	Coding	2241	atgctcatgccaaagatgaa	53	43

-80-

104125 Coding	2291	agtattcttttgcctcgtag	86	44
104126 Coding	2337	ttgtcaatttgatcaatgac	73	45
104127 Coding	2403	tcatgataaaaatagcatgtt	71	46
104128 3' UTR	2758	ccccattcccagagatactc	82	47

5

As shown in Table 2, SEQ ID NOs 9, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 and 47 demonstrated at least 30% inhibition of liver

10 glycogen phosphorylase expression in this experiment and are therefore preferred.

#### Example 17

#### Western blot analysis of liver glycogen phosphorylase protein levels

15 Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 20 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to liver glycogen phosphorylase is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a 25 PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

What is claimed is:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding human liver glycogen phosphorylase, wherein said antisense compound specifically hybridizes with and inhibits the expression of human liver glycogen phosphorylase.

2. The antisense compound of claim 1 which is an antisense oligonucleotide.

3. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46 or 47.

4. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 12, 13, 15, 16, 17, 18, 19, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41, 42, 44, 45 or 47.

5. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

6. The antisense compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.

7. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

8. The antisense compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

9. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

10. The antisense compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.

-82-

11. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

12. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

5 13. The composition of claim 12 further comprising a colloidal dispersion system.

14. The composition of claim 12 wherein the antisense compound is an antisense oligonucleotide.

10 15. A method of inhibiting the expression of liver glycogen phosphorylase in human cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of liver glycogen phosphorylase is inhibited.

15 16. A method of treating a human having a disease or condition associated with liver glycogen phosphorylase comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of liver glycogen phosphorylase is inhibited.

20 17. The method of claim 16 wherein the disease or condition is diabetes.

18. The method of claim 17 wherein the disease or condition is diabetes type II.

RTSP-0556

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number  
**WO 01/05954 A1**

- (51) International Patent Classification<sup>7</sup>: C12N 15/00, 15/11, C12Q 1/68, A61K 48/00
- (21) International Application Number: PCT/US00/19019
- (22) International Filing Date: 12 July 2000 (12.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/357,071 19 July 1999 (19.07.1999) US
- (71) Applicant (for all designated States except US): **ISIS PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).
- (72) Inventors; and  
(75) Inventors/Applicants (for US only): **MONIA, Brett, P.** [US/US]; 7605 Nueva Castilla Way, La Costa, CA 92009 (US). **COWSERT, Lex, M.** [US/US]; 3008 Newshire Street, Carlsbad, CA 92008 (US).
- (74) Agents: **LICATA, Jane, Massey et al.**; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— With international search report.  
— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ANTISENSE MODULATION OF LIVER GLYCOGEN PHOSPHORYLASE EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of liver glycogen phosphorylase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding liver glycogen phosphorylase. Methods of using these compounds for modulation of liver glycogen phosphorylase expression and for treatment of diseases associated with expression of liver glycogen phosphorylase are provided.

WO 01/05954 A1

Docket No.  
RTSP-0240

# Declaration and Power of Attorney For Patent Application

## English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**Antisense Modulation of Liver Glycogen Phosphorylase Expression**

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 12 July 2000 as United States Application No. or PCT International

Application Number PCT/US00/19019

and was amended on \_\_\_\_\_

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

09/357,071

July 19, 1999

Patented

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status)  
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*



26259

PATENT TRADEMARK OFFICE

Herb Boswell, Reg. No. 27,311  
 Laurel Spear Bernstein, Reg. No. 37,280  
 Robert S. Andrews, Reg. No. 44,508  
 Neil S. Bartfeld, Reg. No. 39,901  
 Kenneth H. Tarbet, Reg. No. 43,181  
 Donna T. Ward, Reg. No. 48,271  
 Matthew Grumbling, Reg. No. 44,427  
 of the firm  
 ISIS Pharmaceuticals, Inc.-Carlsbad Research Center  
 2292 Faraday Avenue  
 Carlsbad, California 92008

Send Correspondence to:

Direct Telephone Calls to: *(name and telephone number)*

Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor <b>Brett P. Monia</b>	
Sole or first inventor's signature	Date
Residence <b>Encinitas, California</b>	
Citizenship <b>US</b>	
Post Office Address <b>2306 Casa Hermosa Court</b>	
<b>Encinitas, California 92024</b>	

Full name of second inventor, if any <b>Lex M. Cowser</b>	
Second inventor's signature	Date <b>4/17/02</b>
Residence <b>San Mateo, California</b>	
Citizenship <b>US</b>	
Post Office Address <b>1299 Parrott Drive</b>	
<b>San Mateo, California 94402</b>	



Express Mail Label No.

Page 1 of 3

Docket No.

RTSP-0240

# Declaration and Power of Attorney For Patent Application

## English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**Antisense Modulation of Liver Glycogen Phosphorylase Expression**

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 12 July 2000 as United States Application No. or PCT International Application Number PCT/US00/19019

and was amended on \_\_\_\_\_

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

09/357,071

July 19, 1999

Patented

(Application Serial No.)

(Filing Date)

(Status)  
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)  
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)  
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)



Herb Boswell, Reg. No. 27,311  
Laurel Spear Bernstein, Reg. No. 37,280  
Robert S. Andrews, Reg. No. 44,508  
Neil S. Bartfeld, Reg. No. 39,901  
Kenneth H. Tarbet, Reg. No. 43,181  
Donna T. Ward, Reg. No. 48,271  
Matthew Grumbling, Reg. No. 44,427  
of the firm  
ISIS Pharmaceuticals, Inc.-Carlsbad Research Center  
2292 Faraday Avenue  
Carlsbad, California 92008

Send Correspondence to:

Direct Telephone Calls to: (name and telephone number)

Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor <b>Brett P. Monia</b>	
Sole or first inventor's signature <i>Brett Monia</i>	Date <i>5/2/02</i>
Residence <b>Encinitas, California</b> <i>CA</i>	
Citizenship <b>US</b>	
Post Office Address <b>2306 Casa Hermosa Court</b>	
<b>Encinitas, California 92024</b>	

Full name of second inventor, if any <b>Lex M. Cowsert</b>	
Second inventor's signature	Date
Residence <b>San Mateo, California</b> <i>CA</i>	
Citizenship <b>US</b>	
Post Office Address <b>1299 Parrott Drive</b>	
<b>San Mateo, California 94402</b>	

## SEQUENCE LISTING

<110> Brett P. Monia  
Lex M. Cowser  
ISIS PHARMACEUTICALS, Inc.

<120> ANTISENSE MODULATION OF LIVER GLYCOGEN PHOSPHORYLASE EXPRESSION

<130> RTSP-0056

<150> US 09/357,071

<151> 1999-07-19

<160> 47

<210> 1

<211> 2828

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (114)..(2657)

<400> 1

```

gttgaaagct cctggcgcg cggggcggac tccacccctg cccggcagcc cagcgctcc      60
ggccgcactt ccagctctct gcgcagcccg ccgcgcagcc cgcgcgccca gcc atg      116
                                     Met
                                     1

ggc gaa ccg ctg aca gac cag gag aag cgg cgg cag atc agc atc cgc      164
Gly Glu Pro Leu Thr Asp Gln Glu Lys Arg Arg Gln Ile Ser Ile Arg
                    5                      10                      15

ggc atc gtg ggc gtg gag aac gtg gca gag ctg aag aag agt ttc aac      212
Gly Ile Val Gly Val Glu Asn Val Ala Glu Leu Lys Lys Ser Phe Asn
                20                      25                      30

cgg cac ctg cac ttc acg ctg gtc aag gac cgc aac gtg gcc acc acc      260
Arg His Leu His Phe Thr Leu Val Lys Asp Arg Asn Val Ala Thr Thr
                35                      40                      45

cgc gac tac tac ttc gcg ctg gcg cac acg gtg cgg gac cac ctg gtg      308
Arg Asp Tyr Tyr Phe Ala Leu Ala His Thr Val Arg Asp His Leu Val
                50                      55                      60                      65

ggg cgc tgg atc cgc acg cag cag cac tac tac gac aag tgc ccc aag      356
Gly Arg Trp Ile Arg Thr Gln Gln His Tyr Tyr Asp Lys Cys Pro Lys
                70                      75                      80

agg gaa tat tac ctc tct ctg gaa ttt tac atg ggc cga aca tta cag      404
Arg Glu Tyr Tyr Leu Ser Leu Glu Phe Tyr Met Gly Arg Thr Leu Gln
                85                      90                      95

aac acc atg atc aac ctc ggt ctg caa aat gcc tgt gat gag gcc att      452
Asn Thr Met Ile Asn Leu Gly Leu Gln Asn Ala Cys Asp Glu Ala Ile
                100                      105                      110

tac cag ctt gga ttg gat ata gaa gag tta gaa gaa att gaa gaa gat      500
Tyr Gln Leu Gly Leu Asp Ile Glu Glu Leu Glu Glu Ile Glu Glu Asp
                115                      120                      125

```

gct gga ctt ggc aat ggt ggt ctt ggg aga ctt gct gcc tgc ttc ttg 548  
 Ala Gly Leu Gly Asn Gly Gly Leu Gly Arg Leu Ala Ala Cys Phe Leu  
 130 135 140 145  
 gat tcc atg gca acc ctg gga ctt gca gcc tat gga tac ggc att cgg 596  
 Asp Ser Met Ala Thr Leu Gly Leu Ala Ala Tyr Gly Tyr Gly Ile Arg  
 150 155 160  
 tat gaa tat ggg att ttc aat cag aag atc cga gat gga tgg cag gta 644  
 Tyr Glu Tyr Gly Ile Phe Asn Gln Lys Ile Arg Asp Gly Trp Gln Val  
 165 170 175  
 gaa gaa gca gat gat tgg ctc aga tat gga aac cct tgg gag aag tcc 692  
 Glu Glu Ala Asp Asp Trp Leu Arg Tyr Gly Asn Pro Trp Glu Lys Ser  
 180 185 190  
 cgc cca gaa ttc atg ctg cct gtg cac ttc tat gga aaa gta gaa cac 740  
 Arg Pro Glu Phe Met Leu Pro Val His Phe Tyr Gly Lys Val Glu His  
 195 200 205  
 acc aac acc ggg acc aag tgg att gac act caa gtg gtc ctg gct ctg 788  
 Thr Asn Thr Gly Thr Lys Trp Ile Asp Thr Gln Val Val Leu Ala Leu  
 210 215 220 225  
 cca tat gac acc ccc gag ccc ggc tac atg aat aac act gtc aac acc 836  
 Pro Tyr Asp Thr Pro Glu Pro Gly Tyr Met Asn Asn Thr Val Asn Thr  
 230 235 240  
 atg cgc ctc tgg tct gct cgg gca cca aat gac ttt aac ctc aga gac 884  
 Met Arg Leu Trp Ser Ala Arg Ala Pro Asn Asp Phe Asn Leu Arg Asp  
 245 250 255  
 ttt aat gtt gga gac tac att cag gct gtg ctg gac cga aac ctg gcc 932  
 Phe Asn Val Gly Asp Tyr Ile Gln Ala Val Leu Asp Arg Asn Leu Ala  
 260 265 270  
 gag aac atc tcc cgg gtc ctc tat ccc aat gac aat ttt ttt gaa ggg 980  
 Glu Asn Ile Ser Arg Val Leu Tyr Pro Asn Asp Asn Phe Phe Glu Gly  
 275 280 285  
 aag gag cta aga ttg aag cag gaa tac ttt gtg gtg gct gca acc ttg 1028  
 Lys Glu Leu Arg Leu Lys Gln Glu Tyr Phe Val Val Ala Ala Thr Leu  
 290 295 300 305  
 caa gat atc atc cgc cgt ttc aaa gcc tcc aag ttt ggc tcc acc cgt 1076  
 Gln Asp Ile Ile Arg Arg Phe Lys Ala Ser Lys Phe Gly Ser Thr Arg  
 310 315 320  
 ggt caa gga act gtg ttt gat gcc ttc ccg gat cag gtg gcc atc cag 1124  
 Gly Gln Gly Thr Val Phe Asp Ala Phe Pro Asp Gln Val Ala Ile Gln  
 325 330 335  
 ctg aat gat act cac cct cgc atc gcg atc cct gag ctg atg agg att 1172  
 Leu Asn Asp Thr His Pro Arg Ile Ala Ile Pro Glu Leu Met Arg Ile  
 340 345 350  
 ttt gtg gat att gaa aaa ctg ccc tgg tcc aag gca tgg gag ctc aac 1220  
 Phe Val Asp Ile Glu Lys Leu Pro Trp Ser Lys Ala Trp Glu Leu Asn  
 355 360 365  
 cag aag acc ttc gcc tac acc aac cac aca gtg ctc ccg gaa gcc ctg 1268  
 Gln Lys Thr Phe Ala Tyr Thr Asn His Thr Val Leu Pro Glu Ala Leu  
 370 375 380 385

gag cgc tgg ccc gtg gac ctg gtg gag aag ctg ctc cct cga cat ttg 1316  
 Glu Arg Trp Pro Val Asp Leu Val Glu Lys Leu Leu Pro Arg His Leu  
 390 395 400

gaa atc att tat gag ata aat cag aag cat tta gat aga att gtg gcc 1364  
 Glu Ile Ile Tyr Glu Ile Asn Gln Lys His Leu Asp Arg Ile Val Ala  
 405 410 415

ttg ttt cct aaa gat gtg gac cct ctg aga agg atg tct ctg ata gaa 1412  
 Leu Phe Pro Lys Asp Val Asp Pro Leu Arg Arg Met Ser Leu Ile Glu  
 420 425 430

gag gaa gga agc aaa agg atc aac atg gcc cat ctc tgc att gtc ggt 1460  
 Glu Glu Gly Ser Lys Arg Ile Asn Met Ala His Leu Cys Ile Val Gly  
 435 440 445

tcc cat gct gtg aat ggc gtg gct aaa atc cac tca gac atc gtg aag 1508  
 Ser His Ala Val Asn Gly Val Ala Lys Ile His Ser Asp Ile Val Lys  
 450 455 460 465

act aaa gta ttc aag gac ttc agt gag cta gaa cct gac aag ttt cag 1556  
 Thr Lys Val Phe Lys Asp Phe Ser Glu Leu Glu Pro Asp Lys Phe Gln  
 470 475 480

aat aaa acc aat ggg atc act cca agg cgc tgg ctc cta ctc tgc aac 1604  
 Asn Lys Thr Asn Gly Ile Thr Pro Arg Arg Trp Leu Leu Leu Cys Asn  
 485 490 495

cca gga ctt gca gag ctc ata gca gag aaa att gga gaa gac tat gtg 1652  
 Pro Gly Leu Ala Glu Leu Ile Ala Glu Lys Ile Gly Glu Asp Tyr Val  
 500 505 510

aaa gac ctg agc cag ctg acg aag ctc cac agc ttc ctg ggt gat gat 1700  
 Lys Asp Leu Ser Gln Leu Thr Lys Leu His Ser Phe Leu Gly Asp Asp  
 515 520 525

gtc ttc ctc cgg gaa ctc gcc aag gtg aag cag gag aat aag ctg aag 1748  
 Val Phe Leu Arg Glu Leu Ala Lys Val Lys Gln Glu Asn Lys Leu Lys  
 530 535 540 545

ttt tct cag ttc ctg gag acg gag tac aaa gtg aag atc aac cca tcc 1796  
 Phe Ser Gln Phe Leu Glu Thr Glu Tyr Lys Val Lys Ile Asn Pro Ser  
 550 555 560

tcc atg ttt gat gtc cag gtg aag agg ata cat gag tac aag cga cag 1844  
 Ser Met Phe Asp Val Gln Val Lys Arg Ile His Glu Tyr Lys Arg Gln  
 565 570 575

ctc ttg aac tgt ctg cat gtg atc acg atg tac aac cgc att aag aaa 1892  
 Leu Leu Asn Cys Leu His Val Ile Thr Met Tyr Asn Arg Ile Lys Lys  
 580 585 590

gac cct aag aag tta ttc gtg cca agg aca gtt atc att ggt ggt aaa 1940  
 Asp Pro Lys Lys Leu Phe Val Pro Arg Thr Val Ile Ile Gly Gly Lys  
 595 600 605

gct gcc cca gga tat cac atg gcc aaa atg atc ata aag ctg atc act 1988  
 Ala Ala Pro Gly Tyr His Met Ala Lys Met Ile Ile Lys Leu Ile Thr  
 610 615 620 625

tca gtg gca gat gtg gtg aac aat gac cct atg gtt gga agc aag ttg 2036  
 Ser Val Ala Asp Val Val Asn Asn Asp Pro Met Val Gly Ser Lys Leu  
 630 635 640

aaa gtc atc ttc ttg gag aac tac aga gta tct ctt gct gaa aaa gtc 2084  
 Lys Val Ile Phe Leu Glu Asn Tyr Arg Val Ser Leu Ala Glu Lys Val  
 645 650 655  
  
 att cca gcc aca gat ctg tca gag cag att tcc act gca ggc acc gaa 2132  
 Ile Pro Ala Thr Asp Leu Ser Glu Gln Ile Ser Thr Ala Gly Thr Glu  
 660 665 670  
  
 gcc tcg ggg aca ggc aat atg aag ttc atg cta aat ggg gcc cta act 2180  
 Ala Ser Gly Thr Gly Asn Met Lys Phe Met Leu Asn Gly Ala Leu Thr  
 675 680 685  
  
 atc ggg acc atg gat ggg gcc aat gtg gaa atg gca gaa gaa gct ggg 2228  
 Ile Gly Thr Met Asp Gly Ala Asn Val Glu Met Ala Glu Glu Ala Gly  
 690 695 700 705  
  
 gaa gag aac ctg ttc atc ttt ggc atg agc ata gat gat gtg gct gct 2276  
 Glu Glu Asn Leu Phe Ile Phe Gly Met Ser Ile Asp Asp Val Ala Ala  
 710 715 720  
  
 ttg gac aag aaa ggg tac gag gca aaa gaa tac tat gag gca ctt cca 2324  
 Leu Asp Lys Lys Gly Tyr Glu Ala Lys Glu Tyr Tyr Glu Ala Leu Pro  
 725 730 735  
  
 gag ctg aag ctg gtc att gat caa att gac aat ggc ttt ttt tct ccc 2372  
 Glu Leu Lys Leu Val Ile Asp Gln Ile Asp Asn Gly Phe Phe Ser Pro  
 740 745 750  
  
 aag cag cct gac ctc ttc aaa gat atc atc aac atg cta ttt tat cat 2420  
 Lys Gln Pro Asp Leu Phe Lys Asp Ile Ile Asn Met Leu Phe Tyr His  
 755 760 765  
  
 gac agg ttt aaa gtc ttt gca gac tac gaa gcc tat gtc aag tgt caa 2468  
 Asp Arg Phe Lys Val Phe Ala Asp Tyr Glu Ala Tyr Val Lys Cys Gln  
 770 775 780 785  
  
 gat aaa gtg agt cag ctg tac atg aat cca aag gcc tgg aac aca atg 2516  
 Asp Lys Val Ser Gln Leu Tyr Met Asn Pro Lys Ala Trp Asn Thr Met  
 790 795 800  
  
 gta ctc aaa aac ata gct gcc tcg ggg aaa ttc tcc agt gac cga aca 2564  
 Val Leu Lys Asn Ile Ala Ala Ser Gly Lys Phe Ser Ser Asp Arg Thr  
 805 810 815  
  
 att aaa gaa tat gcc caa aac atc tgg aac gtg gaa cct tca gat cta 2612  
 Ile Lys Glu Tyr Ala Gln Asn Ile Trp Asn Val Glu Pro Ser Asp Leu  
 820 825 830  
  
 aag att tct cta tcc aat gaa tct aac aaa gtc aat gga aat tga 2657  
 Lys Ile Ser Leu Ser Asn Glu Ser Asn Lys Val Asn Gly Asn  
 835 840 845  
  
 actctacaat gtctctagaa aacatagctt cttactgaac ttgaacattt ttacaacatt 2717  
 cactgggtttt tgttttgtta gctaataatc tataatagtt gagtatctct gggaatgggg 2777  
 agggaaatta tatgtaatag agcttaaaaa taaagtgtca atttccaagg a 2828

&lt;210&gt; 2

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<223> PCR Primer

<400> 2

catggggccga acattacaga a

21

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 3

caagaccacc attgccaagt c

21

<210> 4

<211> 27

<212> DNA

<213> Artificial Sequence

<223> PCR Probe

<400> 4

ctgtgatgag gccatttacc agcttgg

27

<210> 5

<211> 19

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 5

gaaggtgaag gtcggagtc

19

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<223> PCR Primer

<400> 6

gaagatggtg atgggatttc

20

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<223> PCR Probe

<400> 7

caagcttccc gttctcagcc

20

<210> 8

<211> 20



<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 8  
ccgccccgcc gcgccaggag 20

<210> 9  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 9  
cgggctgcgc agagagctgg 20

<210> 10  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 10  
cagcgttcg cccatggctg 20

<210> 11  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 11  
tctgtcagcg gttcgcccat 20

<210> 12  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 12  
tgccacgttc tccacgccca 20

<210> 13  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 13  
cttgaccagc gtgaagtgca 20

<210> 14  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 14  
gcgcgaagta gtagtcgcgg 20

<210> 15  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 15  
tccagcgccc caccaggtgg 20

<210> 16  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 16  
cccatgtaaa attccagaga 20

<210> 17  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 17  
atattgcaga ccgaggttga 20

<210> 18  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 18  
ctcttctata tccaatccaa 20

<210> 19  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 19

gcaggcagca agtctcccaa

20

&lt;210&gt; 20

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 20

gccgtatcca taggctgcaa

20

&lt;210&gt; 21

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 21

tacctgccat ccatctcgga

20

&lt;210&gt; 22

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 22

gggcgggact tctcccaagg

20

&lt;210&gt; 23

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 23

tcccgggtgtt ggtgtgttct

20

&lt;210&gt; 24

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 24

ggtgttgaca gtgttattca

20

&lt;210&gt; 25

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

<223> Antisense Oligonucleotide

<400> 25

tccaacatta aagtctctga

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 26

attgtcattg ggatagagga

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 27

tggagccaaa cttggaggct

20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 28

ttctggttga gctcccatgc

20

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 29

acgggccagc gctccagggc

20

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 30

atgcttctga tttatctcat

20

<210> 31

<211> 20

<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 31  
atcagagaca tccttctcag 20

<210> 32  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 32  
cacagcatgg gaaccgacaa 20

<210> 33  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 33  
gaagtccttg aatacttttag 20

<210> 34  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 34  
ctgcaagtcc tgggttgacg 20

<210> 35  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 35  
atcaccagg aagctgtgga 20

<210> 36  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
  
<223> Antisense Oligonucleotide

<400> 36  
aggatgggtt gatcttcact 20

<210> 37  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 37  
acagttcaag agctgtcgct

20

<210> 38  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 38  
cagctttacc accaatgata

20

<210> 39  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 39  
ttccaacccat agggtcattg

20

<210> 40  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 40  
atctgtggct ggaatgactt

20

<210> 41  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 41  
tcatattgcc tgtccccgag

20

<210> 42  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 42

ccacattggc cccatccatg

20

&lt;210&gt; 43

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 43

atgctcatgc caaagatgaa

20

&lt;210&gt; 44

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 44

agtattcttt tgcctcgtag

20

&lt;210&gt; 45

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 45

ttgtcaattt gatcaatgac

20

&lt;210&gt; 46

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 46

tcatgataaa atagcatgtt

20

&lt;210&gt; 47

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 47

ccccattccc agagatactc

20